Bromotheophylline

HCID 11808

Basic information

CAS
10381-75-6
Standard SMILES
Cn1c(=O)c2[nH]c(Br)nc2n(C)c1=O
InChIKey
SKTFQHRVFFOHTQ-UHFFFAOYSA-N
Molecular formula
C7H7BrN4O2
Average molar mass
259.06 g/mol
Monoisotopic mass
257.97524

Names & identifiers

Preferred name
Bromotheophylline
IUPAC
8-bromo-1,3-dimethyl-7H-purine-2,6-dione
English name
8-Bromotheophylline
Molecular formula
C7H7BrN4O2
Molecular weight
259.06

Names & synonyms

BromotheophyllineTheophylline, 8-bromo-1H-Purine-2,6-dione, 8-bromo-3,7-dihydro-1,3-dimethyl-UNII-FZG87K1MQ6FZG87K1MQ6EINECS 233-846-6NSC 164940NSC-1649408-BROMOTHEOPHYLLINE (USP-RS)8-BROMOTHEOPHYLLINE [USP-RS]RefChem:579298-Bromotheophylline
Show more names
Nsc164940AKOS NCG-0005LABOTEST-BB LT001345458-BROMOTHEOPHYLLINE 97%8-Bromotheophylline >8-Bromotheophylline ,97%
10381-75-68-Bromo-1,3-dimethyl-1H-purine-2,6(3H,9H)-dione8-bromo-1,3-dimethyl-7H-purine-2,6-dioneC7H7BrN4O28-bromo-1,3-dimethyl-3,7-dihydro-1H-purine-2,6-dione8-bromo-1,3-dimethyl-3,9-dihydro-1H-purine-2,6-dione8-bromo-1,3-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione8-Bromotheophyline

Database identifiers

CAS
10381-75-6
PubChem CID
11808
DTXSID
DTXSID7044768
UNII
FZG87K1MQ6
EC Number
233-846-6
Nikkaji
J236.804H

Properties

Computed structural properties

XLogP
1
Topological polar surface area
69.3 Ų
Hydrogen bond donors
1
Hydrogen bond acceptors
3
Rotatable bonds
0
Heavy atoms
14

Experimental & physicochemical properties

SolubilitySoluble
Boiling PointDecomposes at 300 ºC
Melting Point295-316 ºC
Dissociation Constants5.45

Physicochemical properties

Melting point
295 · 295-297°C
Boiling point
469.5 · 469.5±55.0 °C(Predicted)
Density
1.862 · 1.862±0.06 g/cm3(Predicted)
storage temp.
Keep in dark place,Inert atmosphere,Room temperature
solubility
DMSO (Slightly), Methanol (Slightly, Heated)
pka
5.45 · pKa 5.45±0.1(H2O t=24) (Uncertain)

Safety & regulation

GHS classification

GHS Classification · 5 items

Warning

H302 (100%): Harmful if swallowed [Warning Acute toxicity, oral];H315 (100%): Causes skin irritation [Warning Skin corrosion/irritation];H319 (100%): Causes serious eye irritation [Warning Serious eye damage/eye irritation];H335 (100%): May cause respiratory irritation [Warning Specific target organ toxicity, single exposure; Respiratory tract irritation]

P261, P264, P264+P265, P270, P271, P280, P301+P317, P302+P352, P304+P340, P305+P351+P338, P319, P321, P330, P332+P317, P337+P317, P362+P364, P403+P233, P405, and P501 (click each P-code to see the statement)

The GHS information provided by 1 company from 1 notification to the ECHA C&L Inventory.

Hazard information

Hazard Classes and CategoriesAcute Tox. 4 (100%);Skin Irrit. 2 (100%);Eye Irrit. 2A (100%);STOT SE 3 (100%)

Safety data

tsca
TSCA listed
ridadr
2811
hs_code
29395900
risk_code
20/21/22
Signal word
Warning
Symbol(GHS)
GHS07

Chemistry & industry

Pharmacology

Protein BindingThis pharmacokinetic property has not been determined.
Pharmacodynamics · 1 item

Bromotheophylline diuretic action will produce an immediate increase in urination frequency. This effect aids in the relief of bloating and menstrual pain. This diuretic function is performed by the an increase in glomerular filtration and a potential effect in the tubular reabsorption as it is established that the administration of these agents produce a rise in the urinary concentration of sodium a chloride and thus, an increase in their rates of excretion.

Mechanism of Action · 1 item

Bromotheophylline is part of the group of the xanthines. As part of this group, it is thought that bromotheophylline increases the permeability of the renal tubule, increases glomerular filtration rate and inhibits the sodium reabsorption in the proximal tubule. It is thought but not confirmed that pamabrom as a mixture seems to have an additional mechanism of action in which the presence of 2-amino-2-methyl-1-propanol produces the suppression of the antidiuretic hormone in the posterior pituitary gland.

Biological Half-LifeThe apparent elimination half-life is registered to be 21.35 hours.
Metabolism/MetabolitesThis pharmacokinetic property has not been determined.
Absorption, Distribution and Excretion · 4 items

When administered after one single oral dosage, bromotheophylline is rapidly absorbed and it reaches a maximal plasma concentration of 2.5 mg/L in 0.78 hours. The mean residence time is registered to be of 12 hours with an AUC in the first 8 hours of 27 mg.h/L.

This pharmacokinetic property has not been determined.

This pharmacokinetic property has not been determined.

This pharmacokinetic property has not been determined.

Uses & manufacturing

General Manufacturing Information1H-Purine-2,6-dione, 8-bromo-3,9-dihydro-1,3-dimethyl-: INACTIVE
Applications · 2 items

DescriptionBromotheophylline is the active moiety of pamabrom, a mixture of 2-amino-2-methyl-propanol and bromotheophylline. From this mixture, bromotheophylline acts as a weak diuretic that has been used along with some analgesics to relieve the symptoms of premenstrual syndrome. Bromotheophylline is categorized on the FDA as a drug substance with an inactive state since March, 1980. It is also approved by Health Canada to be used alone or in combination with [DB00316] in OTC products.

UsesThe active component in the diuretic Diurex.

Suppliers84 total

国药集团化学试剂有限公司86-21-63210123 · [email protected]
梯希爱(上海)化成工业发展有限公司021-67121386 · [email protected]
上海阿拉丁生化科技股份有限公司400-6206333 13167063860 · [email protected]
陕西格列弗生物科技研究有限责任公司13892423764 · [email protected]
韶远科技(上海)有限公司021-50795510 4000665055 · [email protected]

Related reactions

6 records

Compound notes

Loading…